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Abstract
Background: Therapeutic strategies that induce effective neuroprotection and
enhance intrinsic repair mechanisms are central goals for future treatment of
multiple sclerosis (MS), as well as other diseases. Laquinimod (LQ) is an orally
administered, central nervous system (CNS)-active immunomodulator with
demonstrated efficacy in MS clinical trials and a favorable safety and tolerability
profile. Aims: We aimed to explore the pathological, functional, and behavioral
consequences of prophylactic and therapeutic (after presentation of peak
clinical disease) LQ treatment in the chronic experimental autoimmune enceph-
alomyelitis (EAE) mouse model of MS. Materials and methods: Active EAE-
induced 8-week-old C57BL/6 mice were treated with 5 or 25 mg/kg/day LQ via
oral gavage beginning on EAE post-immunization day 0, 8, or 21. Clinical
scores and rotorod motor performance were assessed throughout the disease
course. Immune analysis of autoantigen-stimulated splenocytes, electrophysio-
logical conduction of callosal axons, and immunohistochemistry of white
matter-rich corpus callosum and spinal cord were performed. Results: Prophy-
lactic and therapeutic treatment with LQ significantly decreased mean clinical
disease scores, inhibited Th1 cytokine production, and decreased the CNS
inflammatory response. LQ-induced improvement in axon myelination and
integrity during EAE was functional, as evidenced by significant recovery of
callosal axon conduction and axon refractoriness and pronounced improvement
in rotorod motor performance. These improvements correlate with LQ-induced
attenuation of EAE-induced demyelination and axon damage, and improved
myelinated axon numbers. Discussion: Even when initiated at peak disease, LQ
treatment has beneficial effects within the chronic EAE mouse model. In addi-
tion to its immunomodulatory effects, the positive effects of LQ treatment on
oligodendrocyte numbers and myelin density are indicative of significant, func-
tional neuroprotective and neurorestorative effects. Conclusions: Our results
support a potential neuroprotective, in addition to immunomodulatory, effect
of LQ treatment in inhibiting ongoing MS/EAE disease progression.
Introduction
Inflammation-triggered neurodegenerative damage is ulti-
mately responsible for the primary and secondary progres-
sive phases of multiple sclerosis (MS), and this damage is
particularly refractory to currently approved immunomod-
ulatory or immunosuppressive therapies (Bates 2011; Dutta
and Trapp 2011). Laquinimod (LQ) is a once-daily oral
immunomodulatory agent with potential neuroprotective
properties. In Phase II clinical trials, LQ demonstrated a
favorable safety profile and significantly reduced disease
activity by decreasing the number of active lesions (Polman
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et al. 2005; Comi et al. 2008). In Phase III ALLEGRO and
BRAVO clinical studies, LQ reduced annual relapse rate,
significantly reduced disability progression and brain atro-
phy by 35%, and reduced the risk of sustained disability
(Comi et al. 2012). More recently, LQ was found to
increase levels of brain-derived neurotrophic factor
(BDNF) in the serum of MS patients (Thone et al. 2012).
Experimental autoimmune encephalomyelitis (EAE) is
one of the best mouse models of MS, and it has been used
to understand neurodegenerative mechanisms in the setting
of immune-mediated demyelination (Bannerman et al.
2005; Steinman and Zamvil 2006; Jones et al. 2008). The
EAE model has been used extensively to elucidate immune
mechanisms of currently approved MS drugs (Gasperini
and Ruggieri 2009). Through its ability to reduce infiltrat-
ing cells in the central nervous system (CNS), LQ treatment
within the EAE model has shown promising results by
decreasing spinal cord demyelination and axonal loss
(Brunmark et al. 2002; Yang et al. 2004; Gurevich et al.
2010; Wegner et al. 2010; Aharoni et al. 2012; Bruck et al.
2012). In addition, LQ treatment was shown to alter
monocytes to a Type II phenotype, which direct T cells
toward an anti-inflammatory response (Thone et al. 2012).
In this study, we aimed to further explore the patho-
logical, functional, and behavioral consequences of pro-
phylactic and therapeutic (after presentation of peak EAE
clinical disease) LQ treatment in EAE mice. Detailed
assessment of peripheral immune cell cytokine response
was used to assess peripheral immunomodulation by LQ,
while immunohistochemistry was used to assess immune
cell infiltration into the CNS, axon health, and axon mye-
lination. We and others have shown that CNS structures
other than the spinal cord are negatively affected during
EAE, leading to sensory, motor, and cognitive impair-
ments similar to those seen in MS patients (Hobom et al.
2004; Wensky et al. 2005; Brown and Sawchenko 2007;
Rasmussen et al. 2007; MacKenzie-Graham et al. 2009;
Ziehn et al. 2010). Specifically, corpus callosum (CC)
integrity in MS reflects demyelinating lesions, diffuse tis-
sue damage, and abnormalities in neural connectivity,
making it a potentially useful surrogate marker of clini-
cally significant brain abnormalities (Boroojerdi et al.
1998; Warlop et al. 2008a,b; Ozturk et al. 2010). Thus,
CC integrity was assessed by performing callosal conduc-
tion recordings and immunohistochemistry. Finally, as a
predictive and longitudinal, in vivo functional biomarker
to effectively assay the therapeutic efficacy of LQ, we
measured rotorod motor performance (Tiwari-Woodruff
et al. 2007). Rotorod performance is an established motor
task used to evaluate balance and coordination aspects of
motor function in rodents, and it has potential motor
correlates with the Kurtzke Expanded Disability Status
Scale (EDSS) used to measure disability in MS patients.
Our results demonstrate that both prophylactic and
therapeutic treatment with LQ have significant beneficial
effects in EAE mice. Specifically, LQ treatment attenuates
EAE clinical disease and has immunomodulatory and
neuroprotective effects that yield significant improvements
in axon conduction and myelination. These effects
correlate with significant improvement in rotorod motor
performance. Our results support a potential neuroprotec-
tive, in addition to immunomodulatory effect of LQ treat-
ment in inhibiting ongoing MS/EAE disease progression.
Material and Methods
Animals
Breeding pairs of Thy1-YFP mice (yellow fluorescent pro-
tein under the Thy1 promoter B6.Cg-Tg(Thy1-YFP)16Jrs/
J) originally described by Feng et al. (2000) were purchased
from Jackson Labs (stock number 003709) and were bred
on the C57BL/6 background for more than five generation.
In addition, breeding pairs of PLP_EGFP (proteolipid
protein-enhanced green fluorescent protein) mice were a
kind gift from Dr. Wendy Macklin (University of Colorado,
Denver, CO). These mice were backcrossed to the C57Bl/6
strain for over 10 generation. All mice were bred in-house
at the University of California, Los Angeles, animal facility.
All procedures were conducted in accordance with the
National Institutes of Health (NIH) and approved by the
Animal Care and Use Committee of the Institutional Guide
for the Care and Use of Laboratory Animals at UCLA.
Laquinimod
Laquinimod (originally ABR-215062; RLB#054 M0004)
was synthesized by Teva Pharmaceutical Industries, Ltd.
The compound was dissolved in purified water and
administered daily, by oral gavage, in a volume of 0.1 mL
at 5 mg/kg or 25 mg/kg body weight. Treatment was ini-
tiated at post-immunization day 0 of EAE (pre-EAE+LQ)
or after early (day 8; early post-EAE+LQ) to late (day 21;
peak EAE+LQ) development of clinical manifestations
and continued until the end of the experiment. Control
mice received daily oral gavages of 0.10 mL purified water
(EAE+vehicle).
EAE
Active EAE was induced in 8-week-old male and female
PLP_EGFP C57BL/6 mice (Tiwari-Woodruff et al. 2007;
Crawford et al. 2010; Mangiardi et al. 2011). Specifically,
active EAE was induced via immunization with 200 lg of
myelin oligodendrocyte glycoprotein (MOG) peptide,
amino acids 35–55, in combination with Mycobacterium
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tuberculosis in complete Freund’s adjuvant (CFA) on
post-immunization day 0 and 7. Additionally, mice were
injected with pertussis toxin (PTX) (500 ng/mouse) on
day 0 and 2. Mice were monitored and scored daily for
clinical disease severity according to the standard EAE
grading scale: 0, unaffected; 1, tail limpness; 2, failure to
right upon an attempt to roll over; 3, partial hind limb
paralysis; 4, complete hind limb paralysis; and 5, mori-
bund. Within each treatment group, the mean clinical
score was determined daily, thereby yielding the mean
clinical score for that treatment group. Mice were fol-
lowed clinically for up to 40 days after disease induction.
Rotorod behavioral assay
Motor behavior was tested up to two times per week for
each mouse using a rotorod apparatus (Med Associates,
Inc., St. Albans, VT). Briefly, animals were placed on a
rotating horizontal cylinder for a maximum of 200 sec.
The amount of time the mouse remained walking on the
cylinder without falling was recorded. Each mouse was
tested on a speed of 3–30 rpm and given three trials for
any given day. The three trials were averaged to report a
single value for an individual mouse, and averages were
then calculated for all animals within a given treatment
group. The first two trial days prior to immunization
(day 0) served as practice trials.
Immune responses
Spleens were harvested during deep anesthesia with iso-
flurane prior to perfusion. Splenocytes were stimulated
with the autoantigen MOG 35–55 peptide at 25 lg/mL.
Supernatants were collected after 48 and 72 h, and levels
of tumor necrosis factor (TNF)-a, interferon (IFN)-c,
interleukin (IL)-6, and interleukin (IL)-5 were determined
by Searchlight (Aushon, Billerica, MA), as described pre-
viously (Tiwari-Woodruff et al. 2007).
Histopathology and immunohistochemistry
Formalin-fixed coronal brain sections containing the CC,
in addition to thoracic spinal cord were examined by
immunohistochemistry using various series of cell type-
specific antibodies, as previously described (Tiwari-
Woodruff et al. 2007). In parallel, the CC was dissected
and subjected to electron microscopy (EM) as previously
described (Crawford et al. 2010). The following antibod-
ies were used for immunohistochemistry to detect: axons:
anti-neurofilament (NF200) (1:500, Millipore: MAB1621
and 1:1000, Sigma Aldrich, St. Louis, MO: N4142); astro-
cytes: anti-glial fibrillary acidic protein (GFAP) (1:1000,
Millipore, Billerica, MA: 180063); oligodendrocyte (OL)
progenitors (OLPs): anti-oligodendorcyte transcription
factor 2 (olig2) (Millipore: AB9610) + anti-Ki67 (Milli-
pore: AB9260); mature OLs: anti-CC1 (adenomatus poly-
posis coli, a mature OL marker) (1:1000, Gene Tex,
Irvine, CA: GTX16794); PLP_EGFP fluorescence; myelin:
anti-myelin basic protein (MBP) (1:1000, Millipore:
MAB386, Abcam: 32760); T cells: anti-CD3 (1:1000, Ab-
cam, Cambridge, MA: AB5690); microglia/macrophage/
monocyte: leukocyte antigen marker anti-CD45 (1:500; Mil-
lipore: CBL1326, BD Biosciences, San Jose, CA: 550539),
and damaged axons: anti-amyloid precursor protein (APP;
Abcam: AB11132). The fluorescently tagged secondary
antibody step was performed by labeling with antibodies
conjugated to TRITC/Cy3 (Millipore: AP124C, AP132C),
and Cy5 (Millipore: AP181S; AP187S). IgG-control experi-
ments were performed for all primary antibodies and no
staining was observed under these conditions. To assess the
number of cells, a nuclear stain 4′,6-diamidino-2-phenylin-
dole (DAPI; 2 ng/mL; Molecular Probes (Carlsbad, CA):
D1306) was added for 15 min post-secondary antibody
addition and prior to final washes. Sections were mounted
on slides, allowed to dry, and coverslipped in fluoromont
G (Fisher Scientific, Pittsburgh, PA). For EM, formalin-
and glutaraldehyde-perfused brains were cut sagittally. The
genu area of CC was identified under a dissecting scope
and 4 mm2 blocks (from the mid-CC up to 1/3 splenium,
corresponding to the CC area of plate 40–48 [Crawford
et al. 2009b]) were carefully dissected. These blocks were
further cut in 1 mm sections for Epon embedding.
Microscopy and quantification
Stereological and g-ratio analysis
Immunostaining was quantified using unbiased stereol-
ogy. Dorsal column was delineated using the drawing tool
in Image J (Windows version 1.29 of NIH Image J; down-
loaded from http://rsbweb.nih.gov/ij/; Bethesda, MA).
MBP, GFAP, CD3, and CD45 staining intensities were
quantified within this region. NF200+ and MBP+ axons
within a delineated region of the ventral column of tho-
racic spinal cord sections were quantified. All images
(red, green, blue [RGB]) were converted to grayscale,
split, and separated by color channel using ImageJ. To
avoid experimenter bias, auto-adjustment of brightness
and contrast, as well as threshold of staining signal, was
carried out by NIH software. A Grid Plug-in (Image J)
was used for counting points per area of interest. CC1+
OLs, olig2+ and Ki67+ OLPs, and CD3+ T cells lying
within the CC or spinal cord dorsal column region were
counted manually using 109 or 409 images and compared
blindly between normal, EAE+vehicle, and EAE+LQ treated
groups. Inflammatory cells were quantified by counting the
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number of CD45+ and CD3+ cells that were co-stained
with DAPI+ nuclei in the delineated thoracic spinal cord
dorsal column (and/or delineated CC). Myelin (MBP+)
and astrocytes (GFAP+) were calculated as percent area
intensity from the spinal cord dorsal column (Fig. 2) and
delineated CC. Spinal cord axonal densities were calculated
by counting the number of NF200+ cells in a 409 magnifi-
cation image from the ventral funiculus white matter of
thoracic cords where more coherent and similar diameter
axons are present. Myelinated axonal densities were calcu-
lated by counting axons with a clear ring of MBP+ myelin
staining around them. Damaged axons were calculated by
counting APP+ axons.
For EM analysis, serial ultrathin sections of CC embed-
ded in Epon were stained with uranyl acetate-lead citrate
and analyzed as described in Crawford et al. (2010).
Images at 36009 and 14,0009 magnification were ana-
lyzed using Image J. A grid was used to count axons per
area of interest. The ratio of axon diameter to total fiber
diameter (g-ratio) was measured by dividing the circum-
ference of an axon without myelin by the circumference
of the same axon including myelin (Crawford et al.
2010). For most axons, two encounters were measured.
At least 500 axons were analyzed per treatment group.
Electrophysiological recording procedures
Brain slices (400 lm thick) corresponding approximately
to plates 40–48 in the atlas of Franklin and Paxinos
(2001) were used for electrophysiology recording, as pre-
viously described (Crawford et al. 2010). Compound
action potential (CAP) recordings and axon refractoriness
measurements were performed as previously described
(Crawford et al. 2009a,b). Stimulation used for evoked
CAP was constant current stimulus-isolated square wave
pulses. Axon refractoriness is defined as the reduced excit-
ability of an axon following an action potential. Axon
damage can modify refractoriness and its measurement
represents a diagnostic tool to measure axon health. To
quantify refractoriness, the suppression of a second CAP
response in paired stimulus trials is determined as previ-
ously described.
Statistical analysis
Quantification of immunostaining results was similar to
previous studies (Tiwari-Woodruff et al. 2007; Crawford
et al. 2009b). To quantify immunostaining results, we used
2 sections (about 400 lm apart)/mouse from electrophysi-
ology-recorded brains and 2 sections/mouse from
perfused-fixed brains. There were n = 4 mice from electro-
physiology + n = 4 mice that were perfuse fixed, with a
total of n = 8 mice/per treatment group, for a total of 16
immunostained sections per treatment group. To quantify
electrophysiology results from each treatment group:
recordings from 2 caudal slices 9 4 animals 9 2 experi-
ments = a total of 16 recordings were analyzed. For EM, 10
random caudal area fields/animal at 36009 and 14,0009
magnification were used to quantify the “g-ratio.” Values
are expressed mean  SEM. Statistical analysis of mean
values was carried out using one-way analysis of variance
(ANOVA) and Friedman test (only for clinical scores) or
Bonferroni’s multiple comparison post-test. Differences
were considered significant at the *P < 0.05 level. Statistical
analyses were performed using MicroCal Origin (North-
ampton, MA) or Prism 4 (GraphPad Prism Software Inc.,
La Jolla, CA).
Results
LQ treatment decreases EAE disease
severity equally in female and male mice
First, the dose range finding (DRF) of LQ effective in
reducing the course of EAE clinical disease in male and
female mice was confirmed. To visualize and characterize
the effects of LQ on inflammation, demyelination, and
axon degeneration, chronic EAE was induced in 8-week-
old male and female PLP_EGFP (Mallon et al. 2002) or
Thy1-YFP (Feng et al. 2000) transgenic mice bred on the
C57BL/6 background. Thy1-YFP mice express spectral
variants of green fluorescent protein at high levels in
motor neurons, sensory neurons, and a subset of central
neurons. Axons are brightly fluorescent and no expression
is detectable in non-neural cells. PLP_EGFP mice show
no fluorescence in neuronal cells or axons, but show high
levels of green fluorescent protein in OL and myelin
throughout the CNS.
Chronic EAE was induced using MOG 35–55 peptide
(Mangiardi et al. 2011; Fig. 1A–B). Groups were treated
daily, by oral gavage, with water (vehicle), 5 mg/kg LQ,
or 25 mg/kg LQ beginning on post-immunization day 0
(pre-EAE) or day 8 (early post-EAE), prior to onset of
clinical disease. A group of mice receiving CFA and PTX,
but no MOG peptide, did not develop clinical disease
(normal group). Vehicle-treated EAE mice developed a
persistent, chronic disease course. A significant decrease
in clinical disease development was shown in 5 mg/kg
and 25 mg/kg pre-EAE LQ-treated female mice and they
were similar to the normal group. Pre-EAE LQ-treated
male mice showed a trend toward development of EAE
symptoms but were not significantly different from the
normal group. Even though early post-EAE treatment was
started before development of symptoms, LQ treatment
significantly decreased clinical disease in females and
males by day 21. In both males and females, 25 mg/kg
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LQ was more effective in decreasing EAE clinical scores
than 5 mg/kg LQ (Fig. 1).
Early post-treatmentwith 25 mg/kg, but not
5 mg/kg, LQ reduces Th1 cytokine production
by peripheral immune cells in EAEmice
Previous studies have shown that LQ treatment redi-
rected Type II monocyte differentiation, which was
associated with reduced production of pro-inflammatory
IL-6, IL-12/IL-23 (p40), and TNF, and increased produc-
tion of anti-inflammatory IL-10 (Yang et al. 2004).
Recently, marked decreases in IL-17, IL-5, and IL-10
levels and downregulation of pro-inflammatory cytokines
IL-13, IFN-c, and TNF-a were described in splenocytes
from LQ-treated mice (Wegner et al. 2010). All of these
studies assessed LQ treatment effects on cytokine levels
during early EAE (post-immunization day 13), prior to
the appearance of clinical symptoms. To address the
consistent effects of LQ over time, cytokine levels of
pre-EAE and early post-EAE LQ-treated mice were ana-
lyzed after day 36. Following final clinical score assess-
ment on day 36 (Fig. 1), some mice were euthanized
and their spleens were processed for splenocyte isolation
and subsequent cytokine analysis. Splenocyte cytokine
levels in the early post-EAE 5 mg/kg LQ group were
similar to the vehicle-treated EAE group. However,
decreased levels of IL-10, IL-5, and IL-6 and down-
regulation of Th1-pro-inflammatory cytokines (TNFa,
IFN-c, IL-13, and IL-6) in splenocytes from the early
post-EAE 25 mg/kg LQ group, compared to vehicle-trea-
ted EAE mice, were observed. Matrix metalloproteinase
(MMP-9) was significantly decreased in early post-EAE
25 mg/kg, but not 5 mg/kg, LQ-treated splenocytes as
compared to vehicle-treated EAE splenocytes (Fig. 2).
These results indicate that early post-treatment with
25 mg/kg LQ has anti-inflammatory effects on the
peripheral immune system.
Treatment with LQ attenuates inflammation
and demyelination in spinal cords of chronic
EAE mice
On post-immunization day 36 of EAE, another subset of
mice from the experiment shown in Figure 5 was fixed by
transcardial perfusion for histopathological evaluation and
EM analysis. Spinal cord sections from Thy1-YFP and
PLP_EGFP chronic EAE, vehicle-treated mice contained
multiple areas with significantly decreased “green fluores-
cence,” indicative of neuronal and myelin pathology (Figs.
3 and 5). These areas of low green fluorescence were
accompanied by inflammatory lesions with typical perivas-
cular infiltration and accumulation of mononuclear cells,
as previously seen (Mangiardi et al. 2011). CNS inflamma-
tion in vehicle-treated EAE mice includes activation of
microglia/macrophages and increases in T cell numbers
and cells of the monocyte lineage (Tiwari-Woodruff et al.
2007; Mangiardi et al. 2011). Consecutive thoracic (T1–T5)
spinal cord sections were immunostained and imaged to
show the dorsal column (Fig. 3A). Similar to previous
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Figure 1. Laquinimod (LQ) treatment decreases EAE clinical disease severity equally in female and male mice. Eight-week-old female (A) and
male (B) PLP_EGFP and Thy1-YFP C57BL/6 mice were immunized with MOG 35–55 peptide on post-inoculation day 0 and 7. Groups were treated
daily, by oral gavage, with water (vehicle), 5 mg/kg LQ, or 25 mg/kg LQ beginning on day 0 (pre-EAE) or day 8 (early post-EAE). Mice were
observed daily for clinical signs of EAE and scored on a five point scale. Pretreatment with 5 mg/kg and 25 mg/kg LQ entirely suppressed EAE
clinical signs in both male and female mice. Early post-treatment with 5 mg/kg and 25 mg/kg also suppressed EAE clinical scores starting around
day 20–25 (n = 10–12 mice/group; **P < 0.001, ANOVA Friedman test) as compared to EAE mice receiving vehicle alone. One of three
representative experiments is shown.
668 ª 2013 The Authors. Brain and Behavior published by Wiley Periodicals, Inc.
Laquinimod Treatment Improves Motor Function and Callosal Conduction S. Moore et al.
observations, vehicle-treated EAE mice had numerous mul-
tifocal to coalescing inflammatory cell infiltrates that were
positive for CD45, a pan-leukocyte marker which labels all
infiltrating leukocytes, including T cells (Fig. 3A i–iii) and
CD3+ T cells (Fig. 3A iv). Astrogliosis is also a prominent
feature of the chronic and widespread adaptive CNS
immune response in EAE and MS (Wu and Raine 1992;
Liedtke et al. 1998). A significant increase in GFAP+ (a
reliable astrocyte marker) immunoreactivity was observed
throughout the gray and white matter of spinal cords from
vehicle-treated EAE mice (Fig. 3A ii). Pre-EAE and early
post-EAE LQ treatment significantly attenuated the reactive
astrocyte response, as indicated by a significant decrease in
GFAP staining intensity compared to vehicle-treated EAE
mice (Fig. 3A ii–iv).
Consistent with demyelination, overall CD45+, CD3+,
and GFAP+ cell infiltrates were associated with pallor and
vacuolation in the white matter of spinal cord. Degree of
myelin loss in the dorsal column of thoracic spinal cord
was assessed using MBP immunostaining (Fig. 3B i).
Extensive demyelination occurred at sites of cell infiltrates
in vehicle-treated EAE mice as compared to normal con-
trols. Significantly less demyelination occurred in nearly
all LQ-treated spinal cords (Fig. 3B i). Quantification of
demyelination in vehicle-treated EAE mice by analysis of
MBP staining density in delineated dorsal columns
revealed a ~35% (P < 0.001) decrease in myelin density
as compared with normal controls (Fig. 3B iv). In con-
trast, myelin staining was preserved in 5 mg/kg pre-EAE,
25 mg/kg pre-EAE, and 25 mg/kg early post-EAE LQ-
treated dorsal columns, whereas the 5 mg/kg early post-
EAE LQ-treated dorsal columns showed a trend toward
increased MBP intensity but did not significantly differ
from the vehicle-treated EAE group (Fig. 3B iv).
Considerable evidence now indicates that axonal injury
is prominent in MS and EAE, and it suggests that axonal
injury plays a prominent role in the progression of clini-
cal signs (De Stefano et al. 2003). Here, potential axonal
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Figure 2. Post-treatment with 25 mg/kg, but not 5 mg/kg, laquinimod (LQ) reduces cytokine production by peripheral immune cells in EAE-
induced female mice. EAE was induced as in Figure 1. Female mice from the 5 mg/kg and 25 mg/kg LQ early post-treatment groups were used
for cytokine analysis. On day 36, cytokine production by MOG 35–55 peptide-stimulated splenocytes was determined. No significant change in
cytokine levels was observed with 5 mg/kg LQ early post-treatment. There was an overall decrease in cytokine levels in the 25 mg/kg LQ early
post-treated as compared to the vehicle-treated EAE group. Error bars indicate variability of cytokine values for splenocytes between individual
mice within a given treatment group, with n = 5–8 mice/group. Data are representative of experiments repeated twice (**P < 0.001, t-test).
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Figure 3. Laquinimod (LQ) treatment attenuates inflammation and demyelination in spinal cords of EAE mice. (A) Consecutive Thy1-YFP (green)
thoracic spinal cord sections co-immunostained with CD45 (red, i) or GFAP (red, ii) at 109 magnification are shown from partial images (showing
dorsal column; DC) from normal control, vehicle-treated EAE, 5 mg/kg LQ pretreated EAE, and 25 mg/kg LQ pretreated EAE mice at day 34.
Spinal cords from vehicle-treated EAE mice show large areas of CD45+ and GFAP+ cell staining in the dorsal column as compared with normal
controls, whereas 5 mg/kg and 25 mg/kg LQ pretreated EAE mice show only occasional CD45 and GFAP positivity. Consecutive sections from the
same mice were also scanned at 409 magnification (within DC; designated by the area within the dotted line square) to show the morphology of
CD45+ and GFAP+ cells. Number of CD45+/DAPI+ (iii), CD3+/DAPI+ (v), and GFAP+/DAPI+ (vi) cells per 400 lm2 within the DC were quantified
from consecutive immunostained sections. Vehicle-treated EAE mice had a significant increase in CD45, CD3, and GFAP cells compared to healthy
controls, whereas 5 mg/kg and 25 mg/kg LQ pre- and early post-treated EAE mice did not. A coronal cross section of thoracic spinal cord from a
Thy1-YFP (green) and DAPI-stained (red) vehicle-treated EAE mouse imaged at 49 magnification (iv) is shown. The various regions of the spinal
cord section are labeled as: DC, dorsal column; LF, lateral funiculus; VF, ventral funiculus; GM, gray matter. Statistically significant compared with
normal controls (*P < 0.05; **P < 0.001; 1 9 4 ANOVAs; n = 6–8 mice/group). Data are representative of experiments repeated in their entirety
on another set of EAE mice, with each of the treatment groups. (B) At post-immunization day 34, vehicle-treated EAE mice had reduced MBP (i),
increased APP (ii), and decreased MBP+NF200 (iii) immunoreactivity, compared to normal controls, in the DC and VF of thoracic spinal cord
sections imaged at 109 (i) and 409 (ii, iii) magnification. In contrast, 5 mg/kg and 25 mg/kg LQ pre- and early post-treated EAE mice showed
relatively preserved MBP and NF200 staining. In addition, there was less APP+ immunoreactivity in LQ-treated groups as compared to vehicle-
treated groups (ii). Upon quantification (iv–vi), MBP and NF200 immunoreactivity in the DC was significantly lower in vehicle-treated EAE mice as
compared with normal mice, whereas LQ-treated EAE mice demonstrated no such significant decreases. Quantification revealed less MBP+ and
NF200+ axons in the VF of vehicle-treated mice as compared to normal controls. LQ treatment reversed this trend; that is, there were less APP+
axons and more myelinated (MBP+ and NF200+) axons. Myelin density is presented as percent of normal. Statistically significant compared with
normal controls (*P < 0.05; **P < 0.001; 1 9 4 ANOVAs; n = 6–8 mice/group).
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pathology was evaluated using NF200 and a prototypical
marker of axonal damage, APP. In comparison with nor-
mal controls, EAE mice exhibited numerous APP+ axons
and a significant reduction in the total number of NF200+
axonal profiles in the dorsal column (data not shown) and
ventral funiculus (Fig. 3B ii). In comparison with vehicle-
treated EAE mice, pre-EAE and early post-EAE LQ-treated
mice exhibited an increase in number of NF200+ and sig-
nificantly less APP+ axonal profiles (Fig. 3B ii, v, vi).
To assess the myelination status of NF200+ axons in the
spinal cord of LQ-treated EAE mice, double immunostain-
ing with antibodies to MBP and NF200 revealed relatively
intact myelin rings (red) around axons (green) in normal
and LQ-treated EAE mice (Fig. 3B iii, vii). Quantification
of NF200 staining in the ventral funiculus revealed
49  12% (P < 0.001) reduction in myelinated axons of
vehicle-treated EAE mice compared to healthy controls.
Significant increase in myelinated axons was observed in
LQ-treated pre-EAE and early post-EAE groups as com-
pared to vehicle-treated EAE group (Fig. 3B vi–vii).
Treatment with LQ decreases EAE-induced
callosal conduction and myelination deficit
We have recently shown that CNS structures (i.e., CC,
hippocampus, and cerebellum) other than the spinal cord
are negatively affected during EAE (MacKenzie-Graham
et al. 2009; Ziehn et al. 2010; Mangiardi et al. 2011; Ku-
mar et al. 2013), leading to sensory, motor, and cognitive
impairments similar to those seen in MS patients. Callosal
white matter tracts from EAE brains showed many peri-
ventricular infiltrating lesions around blood vessels (white
dashed box) and scattered throughout the white matter
accompanied by microglia/macrophage and reactive astro-
cyte accumulation and a marked decrease in PLP_EGFP+
OLs (Fig. 4A i; also see Mangiardi et al. 2011). The
pathology observed in EAE callosal axons is similar to the
pathology observed in white matter of EAE-induced
spinal cords. Callosal axons play a significant role in
interhemispheric transfer and integration of sensorimotor
and cognitive information (Singer 1995). To characterize
the functional consequences of CC neuropathology during
EAE, CAPs were recorded in callosal axons (Fig. 4A).
Coronal brain slices with midline-crossing segments of
the CC, corresponding approximately to plates 45–48 in
the atlas of Franklin and Paxinos (2001), were used for
recordings (Fig. 4A i). Typical voltage traces showing two
downward phases of the “N1” and “N2” CAP amplitude,
likely representing fast depolarization from large, myelin-
ated axons and slower depolarization from non-myelinated
axons, respectively, are shown (Mangiardi et al. 2011).
During EAE, both N1 and N2 CAP amplitudes were
decreased to nearly 50% of normal (**P < 0.001, Fig. 4A
i–iii). Treatment with 25 mg/kg LQ during pre-EAE and
early post-EAE induced a significant increase in N1 and
N2 CAP amplitude compared to vehicle treatment
(*P < 0.05).
A recent study demonstrated that clinical, synaptic, and
neuropathological defects in EAE mice were significantly
attenuated by LQ treatment, indicative of potential
neuroprotective effects (Ruffini et al. 2012). To investigate
the effect of LQ on EAE-induced callosal axon
deficits, changes in axon refractoriness were examined as
previously described (Reeves et al. 2005; Crawford et al.
2009a). Axon refractoriness is defined as the reduced
excitability of an axon following an action potential. Axon
damage can modify refractoriness and its measurement
represents a diagnostic tool to measure axon health.
Rightward shifts in these curves correspond to increases
in the refractory recovery cycle in axons and are indica-
tive of functional deficit (Crawford et al. 2010; Mangiardi
et al. 2011). In the normal group, the N1 component
evoked by the second pair of pulses was 50% of the
amplitude of a single pulse presentation at an interpulse
interval (IPI) of 2.2  0.1 msec (Fig. 4A iv). The IPI for
the vehicle-treated EAE group had a slower response of
4.8  0.2 msec, whereas 25 mg/kg LQ pre-EAE- and
early post-EAE-treated callosal axons had a faster IPI of
3.7  0.1 and 3.3  0.2 msec, respectively. The IPI for
the N2 component from vehicle-treated EAE mice
(8.8  2.2 msec) were significantly slower than those of
normal mice (3.2  0.2 msec). LQ treatment caused a
significant recovery, trending to normal levels for pre-
EAE (5.0  0.2 msec) and early post-EAE LQ-treated
animals (4.7  0.2 msec; Fig. 4A v).
Electrophysiology-recorded post-fixed and non-recorded
formalin-fixed brain slices were subjected to immuno-
histochemistry to assess myelin content. Similar to what
was seen in spinal cord sections, and to previous
results, a significant decrease in overall GFP fluores-
cence was observed in vehicle-treated PLP_EGFP mice
(Mangiardi et al. 2011). Compared to normal controls,
vehicle-treated EAE CC displayed a significant decrease
in MBP+ and an increase in infiltrating DAPI+ nuclei
centered on vessels (Fig. 4B). In contrast, 5 mg/kg pre-
EAE and 25 mg/kg pre-EAE and early post-EAE groups
showed a significant improvement in myelin (Fig. 4A,
B). The 5 mg/kg earlypost-EAE LQ-treated group did
not display a significant recovery in callosal myelination
(*P < 0.05, Fig. 4B ii).
To assess the integrity of axon myelination, ultrastruc-
ture analysis of the CC was performed by EM. The ratio
of the inner axonal diameter to the total outer diameter,
termed the “g-ratio,” is widely utilized as a functional
and structural index of optimal axonal myelination.
High magnification images were used to calculate axon
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diameter and myelin thickness to generate mean g-ratios
of all the myelinated and non-myelinated axons within a
given field (Fig. 4C i, ii). At day 36, vehicle-treated EAE
mice showed increased numbers of non-myelinated
(49  6%) and thinly myelinated callosal fibers com-
pared to only 8  4% non-myelinated axons in normal
mice. The calculated g-ratio of vehicle-treated EAE CC
was significantly higher than in normal controls. Number
of non-myelinated axons decreased in EAE groups that
were treated with LQ: 23  5% for pre-EAE+5 mg/kg LQ;
18  4% for pre-EAE+25 mg/kg LQ, 36  7% for post-
EAE+5 mg/kg LQ, and 23  4% for post-EAE+25 mg/kg
LQ as compared to the vehicle-treated group. In addition,
the calculated g-ratio of LQ-treated groups was significantly
lower than those of the vehicle-treated group (Fig. 4C i, ii).
The mean calculated g-ratio of vehicle-treated EAE mice
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(0.90  0.004) was significantly higher than for normal
mice (0.83  0.002). LQ treatment induced a decrease in
axon demyelination and a potential increase in remyelina-
tion, leading to a significant recovery in g-ratio to near
normal levels: early post-EAE+5 mg/kg LQ = 0.87  0.004
and early post-EAE+25 mg/kg LQ = 0.85  0.005 (**P <
0.001, ANOVA).
Therapeutic treatment with 25 mg/kg LQ
during peak EAE attenuates disease scores
and suppresses pro-inflammatory cytokine
production
The 25 mg/kg dose of LQ was most efficient in ameliorat-
ing clinical disease during pre-EAE (post-immunization
day 0) and early post-EAE (day 8). We wanted to test the
effectiveness of LQ treatment in EAE mice exhibiting peak
EAE clinical disease. Importantly, this period comprises
significant demyelination and axon damage due to
inflammatory episodes, and it is a translationally relevant
scenario that more closely mimics therapy in MS patients,
who receive treatment after a disease episode. Groups of
PLP_EGFP and Thy1-YFP female mice were administered
25 mg/kg LQ beginning on day 21 during peak EAE
(peak EAE), when the mean EAE clinical score was 3.0
(partial paralysis). EAE mice started on LQ treatment
at day 0 (pre-EAE) and another group of EAE mice
administered water (EAE+vehicle) were assigned as con-
trols (Fig. 5A). LQ treatment started at peak EAE attenu-
ated a further increase in clinical scores as compared to
vehicle treatment. Eventually, there was a steady decline
in the clinical disease score of this LQ-treated group,
reaching ~1.5 (**P < 0.001, n = 10 animals/group). Fol-
lowing final clinical score assessment on day 36 (Fig. 5A),
some mice were euthanized and their spleens were pro-
cessed for splenocyte isolation and subsequent cytokine
analysis. Even when initiated near peak clinical disease,
25 mg/kg LQ treatment had a remarkable effect on
Figure 4. Treatment with laquinimod (LQ) decreases EAE-induced callosal conduction and myelination deficit. (A) Callosal lesions and
demyelination during chronic EAE. (ii) Representative brain section containing CC white matter tracts from the PLP_EGFP group with late EAE was
immunostained with MBP (green) + DAPI (red) and imaged at 49 magnification. Consecutive brain section from the same group immunostained
with CD45+ (red) microglia/macrophage and imaged at 109 show many infiltrating lesions that are periventricular, around blood vessels (white
dashed box) and scattered throughout the white matter, as well as decreased PLP_EGFP (green) cells and an increase in DAPI+ nuclei (also see
Mangiardi et al. 2011). (ii, iii) Compound action potential (CAP) responses were recorded from slices with midline-crossing segments of the CC
overlying the middorsal hippocampus. Stimulating (Sti) and recording (Rec) electrodes were each placed ~1 mm away from midline. (CC, corpus
callosum; Hip, hippocampus; S1, somatosensory cortex; M, motor cortex). Typical CC CAP from normal (black), vehicle-treated EAE (red), 25 mg/kg
LQ pretreated EAE (magenta), and 25 mg/kg LQ early post-treated EAE (purple) brain slices evoked (at a stimulus of 4 mA) were recorded on post-
immunization day 34. There was a decrease in N1 (fast conducting myelinated component) and N2 (slow conducting, mostly non-myelinated
component) CAP amplitude in the vehicle-treated EAE group. Treatment with 25 mg/kg LQ during EAE inhibited the EAE-induced decrease in N1
and N2 CAP amplitude compared to vehicle treatment. Dashed vertical line represents CAP beyond the stimulus artifact (i). Quantification of N1 (ii)
and N2 (iii) CAP amplitudes in the CC of vehicle-treated EAE and 25 mg/kg LQ pre- and early post-treatment groups was performed. Average C2/
C1 ratios (obtained from plots of mean CAP amplitude) elicited by the second pulse in each paired stimulation (C2), divided by the CAP amplitude
to single pulse stimulation (C1) (Crawford et al. 2009a,b, 2010) were fitted to Boltzmann sigmoid curves (iv–v). A rightward shift in curves for N1
and N2 shows decreased refractoriness in the vehicle-treated EAE group (n = 4). Callosal axons of LQ-treated EAE animals show a significant
increase (a leftward shift in the curve compared to vehicle treatment) in refractoriness of N1 and N2. The interpulse interval (IPI) values
(mean  SD) of the N1 component are: normal = 2.2  0.1 msec, vehicle-treated EAE 4.8  0.2 msec, LQ pre-EAE = 3.7  0.1 msec, and LQ
early post-EAE = 3.1  0.1 msec. The IPI values (mean  SD) of the N2 component are normal = 3.2  0.2 msec, vehicle-treated
EAE = 8.8  2.2 msec, LQ pre-EAE = 5.0  0.2 msec, and LQ early post-EAE = 4.7  0.2 msec. Statistically significant compared with normal
controls at 2–4 mA stimulus strength (*P < 0.05; **P < 0.001; ANOVAs; Bonferroni’s multiple comparison post-test; n = 6 mice/group). (B)
Formalin-fixed brain sections collected from animals perfused on day 34 and brain sections from recorded slices were immunostained with anti-
MBP (red) and imaged at 109 magnification. Vehicle-treated mice had reduced MBP immunoreactivity as compared to normal controls, while
LQ-treated EAE mice showed relatively preserved MBP staining (i). Upon quantification, MBP immunoreactivity in CC was significantly lower in
vehicle-treated EAE mice as compared to normal mice, while EAE mice pre- and early post-treated with LQ demonstrated no significant decreases
(except for the 5 mg/kg LQ early post-treated EAE group). Myelin intensity is presented as percent of normal (*P < 0.05; ANOVAs; Bonferroni’s
multiple comparison post-test; n = 8–10 mice/group). (C) Representative electron micrographs of the CC from normal control, vehicle-treated EAE,
and LQ early post-treated EAE mice show differential levels of axon myelination (i–ii). Compared to normal controls, the CC of vehicle-treated EAE
mice show increased numbers of non-myelinated axons. Early post-treatment with 5 mg/kg and 25 mg/kg LQ resulted in a dramatic increase in
myelinated axons as compared to vehicle-treated EAE mice. Photomicrographs are at 48009. Scale bar is 1 lm. Axon diameter and fiber diameters
of all axons in the field were measured to further quantify the degree of myelination. Axon diameter/fiber diameter (g-ratio) showed a significant
increase in vehicle-treated EAE callosal axons and a dramatic decrease in LQ-treated EAE callosal axons (ii). Calculated g-ratio for callosal axons
(mean  SEM) is normal control = 0.83  0.002, EAE+vehicle = 0.90  0.004, pre-EAE+5 mg/kg LQ = 0.85  0.004, pre-EAE+25 mg/kg
LQ = 0.84  0.005, early post-EAE+5 mg/kg LQ = 0.87  0.04, and early post-EAE+25 mg/kg LQ = 0.85  0.004. At least four mice from each
group were analyzed and a minimum of 500 fibers were measured from each mouse (**P < 0.001; *P < 0.05; ANOVAs; Bonferroni’s multiple
comparison post-test).
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cytokine levels. Similar to the 25 mg/kg pre-EAE LQ
treatment group, splenocyte IL-10, IL-5, IL-13, and IL-6
cytokine levels were significantly decreased in the 25 mg/
kg peak EAE treatment group. In addition, pro-
inflammatory cytokines TNFa, IFN-c, IL-6, and MMP-9
were downregulated in the 25 mg/kg peak EAE and pre-
EAE treatment groups, as compared to the vehicle treat-
ment group (*P < 0.05, **P < 0.001, Fig. 5B).
Therapeutic 25 mg/kg LQ treatment initiated
after onset of EAE clinical disease is
neuroprotective
On day 36 (from the experiment shown in Fig. 5A), a
group of mice underwent transcardial perfusion in prepara-
tion for histopathological evaluation and EM analysis. Sim-
ilar to previous observations, vehicle-treated EAE mice had
numerous multifocal to coalescing inflammatory cell infil-
trates that were CD45+ and GFAP+ combined with a
significant decrease in MBP+ intensity in the spinal cord
dorsal column (Fig. 6A i–iii). Treatment with 25 mg/kg
LQ beginning on day 21 (peak EAE) significantly reduced
the number of infiltrating CD45+ cells and GFAP+ inten-
sity and induced a significant recovery of MBP+ staining
intensity. Similarly, the 25 mg/kg pre-EAE LQ-treated
group had minimal inflammation, decreased reactive astro-
cytes, and little demyelination (Fig. 6A i–iii). Quantifica-
tion of CD45+ cells, GFAP+ cells, and MBP+ staining
intensity showed a significant recovery in myelin density
and a decrease in microglia/macrophages and astrocytes in
peak EAE LQ-treated as compared to the vehicle-treated
EAE group (Fig. 6 v–vii).
In addition to white matter pathology, several studies in
both MS and EAE have indicated the presence of motor
neuron pathology as an aspect of gray matter disease. Vogt
et al. (2009) found a massive loss of lower motor neurons
in MS patients compared to control subjects. This loss led
to a decrease in compound muscle action potential ampli-
tudes and motor unit numbers in MS patients compared to
control subjects (Vogt et al. 2009). In previous studies,
neuron atrophy, but not loss, in MOG-induced EAE of
C57BL/6 mice has been indicated (Bannerman et al. 2005).
By using Thy1-YFP transgenic mice, we were able to char-
acterize and serially count motor neurons in the ventral
horn of T1-T5 spinal cord sections. Spinal cords of vehicle-
treated EAE mice showed similar numbers of motor
neurons compared to normal controls. Analogous to
previous studies, we consistently found significant decreases
in neuronal processes and dendrites, as well as atrophied
cell somas (Fig. 6B i). The pre-EAE LQ-treated group
Figure 5. Therapeutic treatment with 25 mg/kg laquinimod (LQ) after onset of clinical EAE attenuates disease scores and suppresses cytokine
production by peripheral immune cells. (A) PLP_EGFP and Thy1-YFP C57BL/6 female mice were administered 25 mg/kg LQ via oral gavages
beginning on day 21 (purple squares; peak EAE) or day 0 (light purple triangle; pretreated) after initiation of active EAE or water (vehicle; red
circle). Mice were scored using the standard EAE grading scale. EAE scores of mice pretreated with 25 mg/kg LQ were significantly improved
throughout the duration of disease, whereas EAE mice treated with LQ beginning at peak EAE showed significant improvement after 7 days of
continuous treatment, as compared to vehicle-treated EAE mice (**P < 0.001, ANOVA Friedman test). Normal mice did not show any disease and
their clinical scores remained 0 throughout the experiment. Number of mice per treatment group: normal, n = 8; EAE+vehicle, n = 10; pre-
EAE+LQ, n = 10; peak EAE+LQ, n = 15. Data are representative of experiments repeated three times. (B) EAE was induced and treatment was
administered as in Figure 5A. On day 34, mice were euthanized and cytokine production by MOG 35–55 peptide-stimulated splenocytes was
determined. Cytokine levels were each significantly reduced in 25 mg/kg LQ pretreated and with 25 mg/kg LQ post-treated groups. Error bars
indicate variability of cytokine values for splenocytes between individual mice within a given treatment group, with n = 4 mice/group. Data are
representative of experiments repeated twice (*P < 0.05, **P < 0.001, t-test compared to vehicle-treated group).
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Figure 6. Therapeutic treatment with 25 mg/kg laquinimod (LQ) after disease onset reduces inflammation and axon demyelination in spinal cords
of EAE mice. (A) Representative Thy1-YFP (normal and EAE+vehicle) and PLP_EGFP (peakEAE+25 mg/kg LQ) thoracic spinal cord sections (49
magnification) were co-stained with DAPI (red). White square boxes denote various areas of the spinal cord (i). Vehicle-treated EAE spinal cord
had multifocal to coalescing infiltrates in the leptomeninges. No inflammatory nuclei are observed in normal controls, whereas peak EAE+25 mg/
kg LQ shows less DAPI+ cell infiltrates in the lateral funiculus, dorsal column (DC), and ventral funiculus (i). Consecutive Thy1-YFP (green) thoracic
spinal cord sections co-immunostained with CD45 (red, ii) or GFAP (red, iii) at 109 magnification are shown from partial images (showing DC)
from normal control, vehicle-treated EAE, and peak EAE+25 mg/kg LQ mice at day 38 after disease induction. Vehicle-treated EAE spinal cords
had large areas of CD45+ and GFAP+ cell staining in the DC as compared with normal controls, whereas peak EAE+25 mg/kg LQ mice showed a
significant decrease in CD45 and GFAP positivity. Consecutive sections from the same mice were also scanned at 409 magnification (within DC,
designated by the area within the dotted lines in the normal image) to show the morphology of CD45+ and GFAP+ cells (ii, iii). Number of
CD45+/DAPI+ (v), GFAP+/DAPI+ (vi) cells per 400 lm2 and MBP immunoreactivity within the DC were quantified. Compared to normal controls, a
significant increase was seen in vehicle-treated EAE mice but not 25 mg/kg LQ-treated EAE mice. The extent of demyelination was compared by
immunostaining thoracic spinal cord sections with MBP. Myelin density is presented (*P < 0.05; **P < 0.001; 1 9 4 ANOVAs; n = 6–8 mice/
group). Data are representative of experiments repeated in their entirety on another set of EAE mice. (B) The ventral horn and part of the anterior
funiculus of immunostained thoracic spinal cord sections from normal controls, vehicle-treated EAE, and 25 mg/kg LQ-treated EAE Thy1-YFP mice
euthanized on day 34 were imaged at 409 magnification. The number of Thy1-YFP+ motor neurons in the ventral horn did not change between
groups, but the level of Thy1 immunoreactivity in vehicle-treated EAE neurons was significantly weaker. The 25 mg/kg LQ pre- or post-treatment
in EAE mice recovered the level of Thy1-YFP fluorescence in these neurons (i). Consecutive sections immunostained with NF200 (green), MBP
(red), and DAPI (blue) and imaged at 409 showed robust NF200 and MBP immunostaining in the anterior funiculus of normal controls and LQ
pre- and post-treated EAE groups (ii). In contrast, sections from vehicle-treated EAE mice had decreased myelin and axonal staining.
Quantification of Thy1-YFP motor neurons (MN) did not show significant differences in number between groups. Number of NF200+ axons that
were also MBP+ decreased significantly in vehicle-treated EAE mice but not EAE mice pre- or post-treated with 25 mg/kg LQ. Statistically
significant compared with normal controls (**P < 0.001; 1 9 4 ANOVAs; n = 6 mice/group).
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showed similar neuronal numbers, no sign of atrophy, and
no significant process loss, in contrast with the vehicle-
treated EAE group. Most remarkable was the effect of
25 mg/kg LQ treatment after peak EAE disease – no atro-
phy of motor neuron soma, no decrease in processes, and
no dendrite decrease was observed compared to the vehi-
cle-treated EAE group. Quantification of Thy1-YFP or
NF200+ (not shown) neurons colabeled with DAPI showed
no significant differences between groups (Fig. 6B i, iii).
Our previous work has shown a significant decrease in
axon numbers and myelination in white matter of spinal
cord by post-induction day 21 of EAE (Tiwari-Woodruff
et al. 2007; Mangiardi et al. 2011). The effect of LQ treat-
ment during peak disease on axonal pathology and demye-
lination was evaluated. Similar to previous observations,
and in comparison with normal controls, vehicle-treated
EAE ventral funiculus of thoracic spinal cords showed a
significant decrease in myelinated (MBP+ and NF200+)
axons (Fig. 6B ii). In comparison with the vehicle-treated
group, 25 mg/kg LQ pre-EAE and peak EAE groups exhib-
ited an increase in myelinated axon numbers (Fig. 3B ii, v,
vi). Quantification of NF200 staining in the ventral funicu-
lus revealed a 40  12% (P < 0.001) reduction in vehicle-
treated EAE mice as compared with healthy controls,
whereas mice treated with LQ beginning at peak clinical
disease showed a significant recovery to ~70% myelinated
axons of normal controls (Fig. 6B ii, iv).
Therapeutic treatment with 25 mg/kg LQ
after onset of EAE clinical disease
attenuates EAE-induced callosal conduction
deficits
LQ treatment in EAE animals initiated after peak EAE
disease attenuated axon damage and increased axon mye-
lination. If this recovery is sufficient and functional, then
it should afford improved axon conduction as compared
to vehicle-treated EAE animals. CAP recordings of callosal
axons were performed as described above (Crawford et al.
2010). A distinct improvement in peak N1 and N2 CAP
amplitudes was observed in the LQ-treated pre-EAE
group, as previously seen. Surprisingly, LQ treatment after
peak disease resulted in a significant recovery in N1 and
N2 CAP amplitudes, similar to pre-EAE LQ treatment
and normal controls (Fig. 7). Quantification of N1 CAP
amplitudes only is shown (Fig. 7B). To investigate the
therapeutic treatment effect of LQ on EAE-induced axo-
nal deficits, changes in axon refractoriness were estimated
(Fig. 7C). The N1 IPI for the vehicle-treated EAE group
had a slower response of 4.6  0.1 msec, while LQ
pre-EAE treated values of 2.7  0.06 msec were similar
to those of normal animals (2.5  0.01 msec). There was
significant recovery in the peak EAE LQ-treated group to
3.4  0.1 msec (Fig. 7C). Similar trends were seen with
N2 IPIs (data not shown).
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Figure 7. Therapeutic treatment with 25 mg/kg laquinimod (LQ) after onset of clinical EAE attenuates callosal conduction deficits and
demyelination. (A) Compound action potential (CAP) responses were recorded from slices with midline-crossing segments of the CC overlying
the middorsal hippocampus. Typical CC CAP from normal (black), vehicle-treated EAE (red), pre-EAE+25 mg/kg LQ (magenta), and peak
EAE+25 mg/kg LQ (purple) brain slices on day 34 are shown. There is a decrease in N1 and N2 CAP amplitude in the vehicle-treated EAE group,
as well as latency shift in the N2 peak. Both pre-EAE and peak EAE LQ treatment induced an increase in N1 and N2 CAP amplitude compared to
vehicle alone, and normalization of N2 peak latency. (Dashed vertical line represents CAP beyond the stimulus artifact.) (B) Quantification of CAP
amplitudes in the CC of vehicle-treated EAE mice showed a significant reduction in N1 amplitude. LQ pre- and post-treatment showed a
significant improvement in CAP response. (C) Average C2/C1 ratio analysis of LQ-treated EAE callosal axons show a significant increase (a leftward
shift in the curve) in refractoriness of N1 compared to vehicle treatment. The interpulse interval (IPI) values (mean  SD) of N1 component
are normal = 2.6  0.1 msec, EAE+vehicle = 4.5  0.2 msec, pre-EAE+LQ = 2.7  0.1 msec, and peak EAE+LQ = 3.5  0.1 msec. Similar
trends were seen with the N2 IPI (data not shown). Statistically significant compared with normal controls at 2–4 mA stimulus strength
(*P < 0.05; ** P < 0.001; ANOVAs; Bonferroni’s multiple comparison post-test; n = 6 mice/group).
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Therapeutic treatment with 25 mg/kg LQ
significantly increases callosal myelination,
decreases inflammatory cells, and increases
survival of OL
Electrophysiology recorded, post-fixed brain, and forma-
lin-fixed brain sections were used to assess LQ-induced
changes in immune cells, OLs, and axon myelination in
animals treated after peak EAE clinical disease. A signifi-
cant decrease in myelin staining intensity was observed in
the vehicle-treated EAE group, similar to what was seen
before. A significant increase in myelin fluorescence inten-
sity that was not significantly different from the pre-EAE
LQ-treated EAE group was observed in the peak EAE LQ-
treated group (Fig. 8A i, ii). Similar to previous observa-
tions, CNS CD45+ immune cells and GFAP+ reactive
astrocytes were significantly increased in vehicle-treated
EAE animals (Fig. 8B iv). Peak EAE LQ treatment
induced a significant decrease in the number of CD45+
and GFAP+ cells (similar to pre-EAE treatment) as
compared to the vehicle-treated EAE group (Fig. 8B iv).
Increased myelin intensity in LQ-treated EAE mice can
be attributed to an increase in survival of oligodendrocyte
progenitors (OLP) or decrease in OL apoptosis. A direct
PLP_EGFP+ cell count comparison of various treatment
groups revealed a significant decrease in numbers of
PLP_EGFP cells in vehicle-treated EAE mice. In contrast,
pre-EAE and peak EAE LQ-treated mice showed increased
numbers of PLP_EGFP cells. Morphological analysis of
PLP_EGFP cells showed an improvement cell soma and
cell processes in LQ-treated versus vehicle-treated EAE
CC (Fig. 8C i). Because PLP_EGFP positivity does not
distinguish between proliferating and differentiating OL,
consecutive brain sections were co-immunostained with
the proliferation marker Ki67 and olig2, as well as a
marker of mature OL, CC1. In pre-EAE and peak EAE
LQ-treated animals, a significant increase in proliferating
OL (colabeled olig2+ and Ki67+ cells) was observed. In
addition, CC1+ cell numbers were recovered in the peak
EAE LQ-treated group as compared to the vehicle-treated
EAE group (Fig. 8C i–iv).
Therapeutic treatment with 25 mg/kg LQ
significantly decreases EAE-induced motor
deficit as measured by rotorod motor
performance
To assess the functional significance of LQ treatment dur-
ing pre-EAE and peak EAE, EAE mice in a separate
experiment were subjected to a motor test frequently used
to assess spinal cord injury – rotorod motor performance.
EAE was induced in PLP_EGFP mice and animals were
ultimately organized into the following treatment groups:
vehicle, pre-EAE LQ, or peak EAE LQ. 25 mg/kg LQ was
administered to one group of mice beginning on day 0
(pre-EAE). When clinical disease in vehicle-treated EAE
mice reached ~2.5–3 at day 20, treatment with 25 mg/kg
LQ was initiated (peak EAE). EAE scores of pre-EAE
25 mg/kg LQ-treated mice were significantly improved
throughout the duration of disease. Contrastingly, the 25
mg/kg peak EAE LQ group showed significant improve-
ment only after 7 days of continuous treatment, as
compared to vehicle-treated EAE mice. Normal mice did
not show any signs of disease and their clinical scores
remained 0 throughout the experiment (Fig. 9A).
Vehicle-treated EAE mice demonstrated an abrupt and
consistent decrease in the time (seconds) they were able
to remain on the rotorod beginning at day 15 after dis-
ease induction, and this disability remained throughout
the observation period. When the average EAE score
reached ~2.5, vehicle-treated EAE animals that were
switched to 25 mg/kg LQ treatment (at day 20) initially
showed significant motor disability. However, within
5–7 days after initiation of treatment, motor disability
was less severe. By day 30–40, the LQ-treated EAE group
exhibited significant recovery in motor function
(**P < 0.05, ANOVA, n = 10 animals/group; Fig. 9B).
Discussion
Our study demonstrates that LQ treatment is effective in
ameliorating EAE clinical disease even after EAE-induced
inflammation, axon damage, and demyelination have
been initiated. We analyzed callosal white matter integrity
in addition to spinal cord, as the CC in MS reflects
demyelinating lesions, diffuse tissue damage, and abnor-
malities in neural connectivity, making it a potentially
useful surrogate marker of clinically significant brain
abnormalities (Boroojerdi et al. 1998; Warlop et al.
2008a,b; Ozturk et al. 2010). Specifically, LQ inhibits
ongoing demyelination and axon damage in the spinal
cord and CC of EAE mice, leading to substantial recovery
of callosal axon conduction, a functional indicator of
axon myelination and neuroprotection. In addition, LQ
treatment reverses ongoing motor deficit as measured
using standard EAE clinical scoring and rotorod motor
performance. While many reports focus on the prevention
or inhibition of early EAE symptoms using LQ, ours is
the first study to show distinct improvement in axon
myelination, axon conduction, and motor function as a
result of LQ treatment in pre (day 0), early post (day 8),
and peak (~day 21) EAE mice.
We took advantage of PLP_EGFP and Thy1-YFP trans-
genic mice to study the direct effects of LQ treatment on
neurodegeneration and demyelination in EAE. LQ treat-
ment significantly attenuated the loss of GFP fluorescence
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Figure 8. Prophylactic and therapeutic treatment with 25 mg/kg laquinimod (LQ) increases callosal myelination and oligodendrocyte survival but
decreases inflammatory cells. (A) Formalin-fixed brain sections from mice euthanized at post-immunization day 34 were immunostained with anti-
MBP (red) and imaged at 109 magnification. Vehicle-treated EAE mice had reduced MBP immunoreactivity as compared to normal controls, while
LQ-treated EAE mice showed relatively preserved MBP staining (i). Myelin intensity is presented as percent of normal (*P < 0.05; ANOVAs;
Bonferroni’s multiple comparison post-test; n = 8–10 mice/group) (ii). (B) Consecutive brain sections were immunostained with CD45 (red, i) and
GFAP (red, ii) and CC were imaged at 409 magnification. A marked increase in CD45 and GFAP immunoreactivity was observed in the vehicle-
treated EAE group as compared to normal controls. Similar to a decrease in the pre-EAE LQ-treated group, peak EAE+25 mg/kg LQ brains had a
significant decrease in CD45 and GFAP immunoreactivity. This was confirmed by counting the number of CD45+/DAPI+ (iii) and GFAP+/DAPI+ (iv)
cells per 400 lm2 within the dorsal column. (C) To investigate the potential role of oligodendrocytes (OLs) in LQ treatment-induced preservation
of myelin, brain sections from PLP_EGFP mice were colabeled with DAPI (blue) and olig 2, a marker of proliferating OL (co-immunostained with
the proliferation marker Ki67, green; only shown in inset panel C); (i), as well as OL marker APC/CC1 (red, ii). Representative CC sections from
normal controls, vehicle-treated EAE, 25 mg/kg LQ pre- and post-treated EAE mice sacrificed on day 34 and imaged at 409. Compared to the
CC of vehicle-treated EAE mice, the number of PLP_EGFP cells (i), proliferating OL (ii), and OL (iii) were significantly increased in LQ-treated EAE
groups. Quantification of the number of PLP_EGFP (iv) costained olig2 + Ki67 cells (v) and CC1+ cells (vi) per 400 lm2 indicated a significant
decrease in vehicle-treated EAE mice compared to normal controls. LQ treatment caused a significant increase in all three as compared to vehicle-
treated EAE mice (*P < 0.05; **P < 0.001; ANOVAs; Bonferroni’s multiple comparison post-test; n = 8–10 mice/group).
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in neurons, axons, and OLs of the CNS. Most remarkable
was the increased axon remyelination, axon conduction,
and the significant recovery in proliferating and mature
OL numbers of EAE animals treated with LQ after peak
disease. This recovery correlated with LQ-mediated sup-
pression of cytokine production and reduction in infil-
trating immune cells in the CNS. Previous studies have
also shown LQ-induced neuroprotection in EAE CNS
(Ruffini et al. 2012), which correlates with suppression of
cytokine production and reduction in infiltrating immune
cells (Yang et al. 2004; Wegner et al. 2010; Aharoni et al.
2012; Bruck et al. 2012). In the present study, peripheral
cytokine levels determined after post-immunization day
30 of EAE following 25 mg/kg LQ treatment were similar
to levels observed at day 13 (i.e., downregulation of pro-
inflammatory cytokines IL-13, IL-17, IFN-c, and TNF-a
(Wegner et al. 2010). In addition, there was a significant
decrease in IL-4, IL-5, and IL-6 cytokines. Our findings of
LQ-induced reduction in IL-10 levels in EAE mice are
similar to Wegner et al. (2010) and contrast the increase
in IL-10 levels reported by Yang et al. (2004). MMP have
a crucial function in the migration of peripheral inflam-
matory cells into the CNS and levels of MMP-9 are
elevated in MS and EAE. The 25 mg/kg LQ treatment
during pre-EAE and peak EAE significantly decreased
MMP-9 levels. Taken together, our findings suggest that
LQ protects myelin and axons by decreasing pro-inflam-
matory cytokines and impairing the migratory capacity of
inflammatory cells.
Reactive astrogliosis is a prominent feature of the
chronic and widespread adaptive immune inflammation
of the CNS that occurs during EAE and MS (Eng 1985).
Reactive astrocytes are responsible for the production of
pro-inflammatory molecules (e.g., cytokines, chemokines,
growth factors, nitric oxide), growth-inhibitory molecules,
and increased production of NFjB-dependent pro-inflam-
matory molecules. These molecules are detrimental to
oligodendrocyte survival, remyelination, and functional
recovery (Brambilla et al. 2009; Chang et al. 2012). A
recent study using cuprizone diet-induced demyelination
in mice demonstrated that LQ treatment reduces the
inflammatory response in astrocytes by interfering with
astrocytic NF-jB activation in vivo and in vitro (Bruck
et al. 2012). Similarly, in the present study, LQ treatment
significantly decreased the number of reactive astrocytes
in the spinal cord and CC of pre-, early post-, and peak-
EAE mice. Such findings point to an immunomodulatory
mechanism through which LQ acts to uphold OL health
and blunt demyelinating effects of EAE.
Notwithstanding, LQ’s mechanisms of action are still
being investigated. LQ is a small molecule that passively
enters all cell types. A direct effect of LQ on astrocytes via
modulation of NF-jB to reduce inflammatory response, or
an indirect effect on various cell types and increase in
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Figure 9. Prophylactic and therapeutic treatment with 25 mg/kg laquinimod (LQ) significantly decreases EAE-induced motor deficit, as measured
by rotorod motor performance. (A) In a separate experiment, PLP_EGFP C57BL/6 female mice were given 25 mg/kg LQ via oral gavage beginning
on day 20 (purple squares; peak EAE) or day 0 (light purple triangle; pre-EAE) after initiation of active EAE. Another group of EAE mice was
administered water (vehicle) by oral gavage (red circle). Mice were scored using the standard EAE grading scale. EAE scores of LQ pretreated mice
were significantly improved throughout the duration of disease, whereas LQ post-treated mice showed significant improvement after 7 days of
continuous treatment compared to vehicle-treated EAE mice. Normal mice did not show any disease and their clinical scores remained zero
throughout the experiment. (**P < 0.001; ANOVA; Friedman test; n = 10 mice/group). (B) To assess the clinical significance of LQ treatment
during pre-EAE and peak EAE, mice from Figure 9A were subjected to a motor test frequently used to assess spinal cord injury-rotorod
performance. Vehicle-treated EAE mice (red) demonstrated an abrupt and consistent decrease in time (seconds) they were able to remain on the
rotorod beginning at day 15 after disease induction, and this disability remained throughout the observation period. When a group of vehicle-
treated EAE mice were switched to 25 mg/kg LQ treatment at day 20 (purple square), the time point at which the mean EAE score reached ~2.5,
disability continued but was less severe. However, later, at day 30–40, the LQ-treated peak EAE group exhibited significant recovery. Normal
(black) and 25 mg/kg LQ pretreated group (magenta) did not show any motor deficit. (**P < 0.05; ANOVA; n = 10).
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growth factors, may contribute to cell survival, axon myeli-
nation, and neuroprotection in EAE and MS (Aharoni
et al. 2012; Bruck et al. 2012; Thone et al. 2012). One of
the many neurotrophic factors essential for neuronal func-
tion and myelination is BDNF. During EAE, BDNF mRNA
and protein are significantly decreased, specifically in
neurons, though higher immunoreactivity is observed in
reactive astrocytes and immune cells around the lesions
(Linker et al. 2010). A recent study showed that LQ
treatment during EAE restores BDNF expression to normal
levels (Aharoni et al. 2012). Similarly, a significant eleva-
tion of serum BDNF levels in relapse remitting MS (RRMS)
patients receiving LQ therapy was observed (Thone et al.
2012). BDNF/tyrosine kinase receptor B (TrkB)-stimulated
intracellular signaling is critical for neuronal survival,
morphogenesis, plasticity, normal OL development, and
axon myelination (Hetman et al. 1999; Linker et al. 2009;
Numakawa et al. 2010; Vondran et al. 2010; Xiao et al.
2010; VonDran et al. 2011). LQ treatment-induced increase
in BDNF and modulation of immune and astrocyte cell
signaling could be responsible for improvement in OL
proliferation/and survival that leads to improved axon
remyelination and neuroprotection observed.
In summary, LQ treatment asserts a significant positive
effect on axon myelination during EAE. LQ treatment
caused a significant improvement in clinical scores even
after peak EAE disease, when significant axon demyelina-
tion, axon damage, and OL apoptosis have already been
established (Tiwari-Woodruff et al. 2007; Mangiardi et al.
2011). Rotorod motor performance by EAE mice can be
correlated to the motor aspect of EDSS scores in MS
patients, and it can be an essential biomarker for therapeu-
tic MS drugs. At peak disease, EAE animals are unable to
remain on the rotorod due to significant motor deficits.
Upon treatment with LQ (before onset of or after peak
disease), EAE animals exhibited significant motor improve-
ment. Motor performance improvement correlated with
improved callosal conduction and cell survival in the CNS.
These findings strongly suggest that LQ treatment has
significant and functional beneficial effects on neuron
survival, decreasing axon damage, improving survival and
proliferation of OLs, and increasing myelination/remyeli-
nation. A recent study emphasized that endogenous remye-
lination of the cerebral cortex can occur in individuals with
MS, regardless of disease duration (Chang et al. 2012).
With this in mind, LQ treatment could be beneficial to
both RR and progressive forms of MS.
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